Infliximab biosimilars average market share (MS) was 20% in 2015 and 45% in 2016 and it was assumed a 10% increase in 2017 and a 5% in subsequent years. Etanercept biosimilars MS was assumed 20% in 2016, 40% in 2017 (2^nd biosimilar in the market), 50% in 2018, 55% in 2019 and 60% in 2020. Adalimumab biosimilars MS was assumed 30% in 2018, 50% in 2019 and 60% in 2020. Infliximab biosimilar average discount was 40% in 2015 and 50% in 2016 assuming further 2.5% in subsequent years. Etanercept biosimilar average discount was 35% in 2016 assuming further 10% discount in 2017 and further 2.5% in subsequent years. For adalimumab biosimilar, 35% discount was assumed in 2018 with further 2.5% in subsequent years. Originator prices were assumed to decrease by 10% in first 2 years of biosimilar introduction and by 20% in subsequent years. RESULTS:  Biosimilar introduction of the 3 anti-TNFs in Europe is likely to result in savings of $11.44b between 2015-2020; i) infliximab: $5.31b, ii) etanercept: $2.95b & iii) adalimumab: $3.18b. CONCLUSIONS: Biosimilars of these 3 anti-TNFs will provide significant savings to the healthcare systems across Europe contributing to their sustainability.